Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 704

1.

PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor.

Litvinov IV, Antony L, Dalrymple SL, Becker R, Cheng L, Isaacs JT.

Prostate. 2006 Sep 1;66(12):1329-38.

PMID:
16835890
2.

Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.

Zaia A, Fraizer GC, Piantanelli L, Saunders GF.

Anticancer Res. 2001 Jan-Feb;21(1A):1-10.

PMID:
11299720
3.

Androgenic up-regulation of androgen receptor cDNA expression in androgen-independent prostate cancer cells.

Dai JL, Maiorino CA, Gkonos PJ, Burnstein KL.

Steroids. 1996 Sep;61(9):531-9.

PMID:
8883219
4.
5.

Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.

Sun A, Tang J, Hong Y, Song J, Terranova PF, Thrasher JB, Svojanovsky S, Wang HG, Li B.

Prostate. 2008 Mar 1;68(4):453-61. doi: 10.1002/pros.20723.

PMID:
18196538
6.
8.

Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line.

Mizokami A, Gotoh A, Yamada H, Keller ET, Matsumoto T.

J Urol. 2000 Sep;164(3 Pt 1):800-5.

PMID:
10953159
9.

Cell cycle regulator cdk2ap1 inhibits prostate cancer cell growth and modifies androgen-responsive pathway function.

Zolochevska O, Figueiredo ML.

Prostate. 2009 Oct 1;69(14):1586-97. doi: 10.1002/pros.21007.

PMID:
19585490
11.
12.

Androgen receptor functioned as a suppressor in the prostate cancer cell line PC3 in vitro and in vivo.

Yu SQ, Han BM, Shao Y, Wu JT, Zhao FJ, Liu HT, Sun XW, Tang YQ, Xia SJ.

Chin Med J (Engl). 2009 Nov 20;122(22):2779-83.

PMID:
19951614
13.

Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer.

Kaseb AO, Chinnakannu K, Chen D, Sivanandam A, Tejwani S, Menon M, Dou QP, Reddy GP.

Cancer Res. 2007 Aug 15;67(16):7782-8.

14.

An androgen-independent androgen receptor function protects from inositol hexakisphosphate toxicity in the PC3/PC3(AR) prostate cancer cell lines.

Diallo JS, Péant B, Lessard L, Delvoye N, Le Page C, Mes-Masson AM, Saad F.

Prostate. 2006 Sep 1;66(12):1245-56.

PMID:
16705740
15.

Androgen receptor and TGFbeta1/Smad signaling are mutually inhibitory in prostate cancer.

van der Poel HG.

Eur Urol. 2005 Dec;48(6):1051-8. Epub 2005 Oct 14.

PMID:
16257107
16.

Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor.

Heisler LE, Evangelou A, Lew AM, Trachtenberg J, Elsholtz HP, Brown TJ.

Mol Cell Endocrinol. 1997 Jan 3;126(1):59-73.

PMID:
9027364
17.

Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation.

Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, Schröder FH, van Steenbrugge GJ.

Prostate. 2002 Mar 1;50(4):203-15.

PMID:
11870798
18.

Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines.

Venkateswaran V, Klotz LH, Fleshner NE.

Cancer Res. 2002 May 1;62(9):2540-5.

19.

ACTR/AIB1/SRC-3 and androgen receptor control prostate cancer cell proliferation and tumor growth through direct control of cell cycle genes.

Zou JX, Zhong Z, Shi XB, Tepper CG, deVere White RW, Kung HJ, Chen H.

Prostate. 2006 Oct 1;66(14):1474-86.

PMID:
16921507
20.

Persistent p21Cip1 induction mediates G(1) cell cycle arrest by methylseleninic acid in DU145 prostate cancer cells.

Wang Z, Lee HJ, Chai Y, Hu H, Wang L, Zhang Y, Jiang C, Lü J.

Curr Cancer Drug Targets. 2010 May;10(3):307-18.

PMID:
20370687

Supplemental Content

Support Center